The Actelion's Management Honoured in 2011 Institutional Investors All-Europe Executive Team Awards

Friday, 11. March 2011 07:00
Actelion Pharmaceuticals Ltd /
The Actelion's Management Honoured in 2011 Institutional Investors All-Europe
Executive Team Awards
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.

Ranked 2(nd) Most Honoured Company Overall and Leading Biotechnology Company

ALLSCHWIL/BASEL, SWITZERLAND - 11 March 2011 - Actelion Ltd (SIX: ATLN) is
pleased to announce that its Executive Team was ranked 2nd "Most Honoured
Company" overall in the in the 2011 Institutional Investor All-Europe Awards
[alongside another Swiss company, Holcim.]  Actelion was ranked as the 3rd Most
Honoured Company in 2010.

The results of the Institutional Investor survey reflect the opinions from more
than 800 investment professionals at 435 buy-side firms and more than 1,200
sell-side analysts from almost 150 institutions about the executive teams of
European companies.

The "Most Honoured Company" the award is based on the votes received for the
Executive Team across a total of four categories: Best CEO, Best CFO, Best IR
Officer and Best Company IR Overall.

Within the Biotechnology sector, Actelion made a clean sweep of the awards with
Jean-Paul Clozel ranking 1st amongst the sectors CEOs, Andrew J. Oakley ranking
1st amongst the sectors CFOs and Roland Haefeli ranking 1st in the IR Officer
category.  As a result Actelion ranked as the leading Biotechnology Company in
the 2011 Institutional Investor All European Executive Team award.

Jean-Paul Clozel: "We are pleased to have received this positive feedback from
shareholders and the broader European investment community.  We place a great
deal of emphasis on our investor relations activities which are focused on being
fully transparent on our strategy and operational performance. The result of
this survey has also been reflected in the strong support for our strategy that
we have received during our recent discussions with shareholders."


###

Actelion Ltd.

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(®), an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,400 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI(®)).

Actelion's Annual General Meeting of Shareholders approving the Business Report
of the year ending 31 December 2010 will be held on 5 May 2011. In order to
attend and vote at the Annual General Meeting of Shareholders, shareholders must
be registered in the Company's shareholders register by 28 April 2011 at the
latest.


For further information please contact:

Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com






--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;

Press Release PDF:
http://hugin.info/131801/R/1496231/431928.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE

[HUG#1496231]
Related Links: Actelion Pharmaceutical Ltd, 
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.